Dietary supplement to prevent bowel injury during radiation for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether a special dietary supplement can help protect the rectum from radiation damage during chemoradiation for locally advanced rectal cancer. If it works, it may reduce painful bowel symptoms like frequent stools and cramping.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal adenocarcinoma that has spread into the rectal wall or nearby lymph nodes but not to distant organs.
- You are scheduled to receive radiation therapy (short or long course) combined with a fluoropyrimidine-based chemotherapy (like capecitabine or 5-FU).
- You are physically active and able to care for yourself (ECOG 0 or 1).
- You have fewer than 3 bowel movements per day and no significant abdominal pain or rectal cramping.
- You have not had surgery to remove part of your rectum or intestines before.
- You do not have active inflammatory bowel disease, severe diarrhea, or previous pelvic radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a dietary supplement to help heal damage inside the rectum caused by pelvic radiation therapy. If you have mild to moderate rectal bleeding but no signs of cancer recurrence, you may be able to join.
This study tests a combination of a special diet supplement (beta-hydroxybutyrate), short radiation therapy, immunotherapy, and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improve treatment outcomes.
This trial tests whether giving an enema (a liquid medicine inserted into the rectum) called Bergmann can help prevent rectal injury caused by radiation therapy in patients with rectal cancer. If you are about to start short-course radiation, this treatment might reduce side effects like pain or bleeding.
This trial studies whether adding TAS-102 (a chemotherapy medicine) to radiation given before treatment improves outcomes for certain locally advanced rectal cancers. It may help by trying to shrink the tumor before the next steps of care.
This study tests whether a fecal (stool) transplant can help heal rectal damage caused by pelvic radiation. The treatment may decrease bleeding and improve symptoms for people whose supportive care hasn't worked well.
This trial tests a shorter radiation course combined with two chemotherapy drugs and an immunotherapy drug for people with locally advanced rectal cancer that is microsatellite stable. The goal is to shrink the tumor before surgery, which may improve outcomes with fewer side effects.
Hear when a new Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.